NHS QIS issues NICE Technology Appraisal Guidance No 55 on the use of paclitaxel in the treatment of ovarian cancer to NHSScotland.
NHS Quality Improvement Scotland issues advice on paclitaxel for ovarian cancer
The following has been considered by NHS Quality Improvement Scotland through its revised procedure of processing of NICE Guidance.
NICE Technology Appraisal Guidance No 55 - The use of paclitaxel in the treatment of ovarian cancer.
As no important differences were identified for the NICE Guidance, NHS Quality Improvement Scotland advises that it is as valid for Scotland as for England and Wales and no other publication on the NICE Guidance will be issued by NHS Quality Improvement Scotland.
NHS Quality Improvement Scotland advice represents the evidence-based view of NHS Quality Improvement Scotland. NHSScotland should take account of this advice from NHS Quality Improvement Scotland and ensure that recommended drugs or treatments are made available to meet clinical need. However, this advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer.
Hard copies of the NICE Guidance are available from NHS Quality Improvement Scotland (contact Shonagh Buchanan, tel 0141 225 6993) and all NICE Guidance and NHS Quality Improvement Scotland Comments are available on this website.
NICE Technology Appraisal Guidance No. 55 - Paclitaxel Overarian Review (PDF, 24 pages) .